Numerous advances have been made in the pharmacological management of HF including angiotensin receptor/neprilysin inhibitors and sodium glucose co-transporter 2 (SGLT-2) inhibitors [94]. This evidence concerns the gene SLC5A2 and hydrops fetalis.